Genmab — Oktober 2018
-
JNJ Q3 kommer tirsdag 16 oktober inden aabning. Det er svært at vurdere Genmab paa den korte bane og man ved ikke hvornaar en ev.t stor spiller begynder at supplere. Derudover begynder kursen vel ogsaa at være interessandt med henblik paa etv. opkøb af et stort pharma firma
-
Servicemeddelse: "Nå psyken driller". Teknisk update Ambu, Veloxix, Bioporto og Bavarin.http://www.proinvestor.com/debat
/76299 -
Hvis ikke RoW arter sig som forventet, kan vi basalt risikere en ordentlig røvfuld den 16. når JNJ Q3 kommer.
-
Den overskrift passer vist meget på Genmab for tiden.

-
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154747/ Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
-
Jeg skriver jo "hvis Row...."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind